NASDAQ:CRSP

Crispr Therapeutics Stock News

etoro logo Buy CRSP
*Your capital is at risk
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Indexes are extending bull market gains, reaching new records. It's not too late to get in on the action -- history suggests this bull market could have much farther to go.
National Bank of Canada FI lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 63.7% during the fourth quarter, according to the company in its most recent 13F filing wit

Is CRISPR Therapeutics Stock a Buy?

09:30am, Friday, 17'th May 2024
CRISPR develops cutting-edge therapies that could be transformative. The gene-editing specialist has launched its first approved treatment.
They say the best time to invest was 20 years ago. And indeed, that's not too long after the early 2000s recession bottomed out.
CRISPR reported rising losses on deeply lower revenue last week. The gene-editing biotech is, however, making progress on several therapies, and ready to bring its first treatment to market.
The healthcare sector has attractive stocks for any investment strategy. Pfizer has an impressive product pipeline and an attractive valuation as well.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
As investors, we are always aiming to reevaluate our portfolios and make additions. However, we can often get lost in the vastness of the markets when deciding on just a handful of companies.
The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always look for
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to loss of $0.67 per share a year ago.
-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected-
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma -
Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untr
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE